Huntington Study Group
15
1
2
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
20%
3 trials in Phase 3/4
18%
2 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research
Role: lead
Longitudinal Endpoint Assessment of Disease Burden in HD
Role: lead
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Role: collaborator
Prospective Huntington At Risk Observational Study
Role: lead
Making HD Voices Heard
Role: lead
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Role: collaborator
Development of the Virtual Unified Huntington's Disease Rating Scale
Role: lead
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Role: collaborator
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Role: collaborator
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
Role: collaborator
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
Role: collaborator
Cooperative Huntington's Observational Research Trial
Role: collaborator
Ursodiol in Huntington's Disease
Role: collaborator
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
Role: collaborator
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
Role: collaborator
All 15 trials loaded